Tyra Biosciences (NASDAQ:TYRA) Trading Up 6.2% – What’s Next?

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s share price was up 6.2% during trading on Monday . The company traded as high as $26.70 and last traded at $26.85. Approximately 256,793 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 903,935 shares. The stock had previously closed at $25.29.

Analysts Set New Price Targets

Several analysts have issued reports on TYRA shares. Wolfe Research initiated coverage on Tyra Biosciences in a report on Tuesday, May 19th. They set a “peer perform” rating for the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $42.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Friday, July 17th. Bank of America boosted their price objective on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Finally, JonesTrading assumed coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.90.

Tyra Biosciences Trading Up 3.2%

The business’s 50 day moving average is $29.75 and its two-hundred day moving average is $32.52. The company has a market cap of $1.56 billion, a PE ratio of -10.88 and a beta of 0.77.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, equities research analysts predict that Tyra Biosciences, Inc. will post -2.74 EPS for the current fiscal year.

Institutional Trading of Tyra Biosciences

Several institutional investors have recently made changes to their positions in TYRA. Jupiter Topco LLC bought a new stake in Tyra Biosciences during the 2nd quarter valued at approximately $139,161,000. Janus Henderson Group PLC lifted its holdings in Tyra Biosciences by 32.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock worth $148,867,000 after purchasing an additional 955,147 shares in the last quarter. Commodore Capital LP boosted its stake in Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after purchasing an additional 2,150,000 shares during the period. BlackRock Inc. bought a new position in Tyra Biosciences in the 2nd quarter worth approximately $96,841,000. Finally, Farallon Capital Management LLC grew its holdings in Tyra Biosciences by 80.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after buying an additional 923,000 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.